REGENXBIO (NASDAQ:RGNX) Upgraded by Raymond James to “Moderate Buy” Rating

REGENXBIO (NASDAQ:RGNX) was upgraded by investment analysts at Raymond James to a “moderate buy” rating in a note issued to investors on Thursday,Zacks.com reports.

RGNX has been the subject of a number of other research reports. Royal Bank of Canada reiterated an “outperform” rating and set a $30.00 target price on shares of REGENXBIO in a research report on Tuesday, January 21st. Chardan Capital reissued a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a report on Wednesday, November 20th. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday. HC Wainwright reiterated a “buy” rating and issued a $36.00 price target on shares of REGENXBIO in a report on Wednesday, January 15th. Finally, Morgan Stanley reissued an “overweight” rating and set a $22.00 price target on shares of REGENXBIO in a research note on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $35.64.

REGENXBIO Stock Performance

Shares of RGNX stock opened at $8.21 on Thursday. REGENXBIO has a 52-week low of $6.56 and a 52-week high of $28.80. The stock has a market cap of $406.72 million, a price-to-earnings ratio of -1.63 and a beta of 1.29. The firm has a fifty day moving average of $8.11 and a 200-day moving average of $10.10.

Hedge Funds Weigh In On REGENXBIO

Large investors have recently modified their holdings of the business. GAMMA Investing LLC grew its stake in REGENXBIO by 273.1% in the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,510 shares in the last quarter. FMR LLC grew its holdings in REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,656 shares during the period. nVerses Capital LLC increased its position in REGENXBIO by 183.3% during the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after buying an additional 2,200 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in REGENXBIO by 64.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 3,720 shares during the period. Finally, Erste Asset Management GmbH bought a new position in shares of REGENXBIO during the 3rd quarter worth approximately $140,000. 88.08% of the stock is currently owned by institutional investors and hedge funds.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.